Could Flow Cytometry Provide New Prognostic Markers in Colorectal Cancer?

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Aug 29

PMID 39200895

Authors

Vaia Georvasili

Georgios Markopoulos

Evangeli Lampri

Georgios Lianos

George Vartholomatos

Michail Mitsis

Christina Bali

Affiliations

Soon will be listed here.

Abstract

: Colorectal cancer (CRC) is still accompanied by significant mortality, which poses the necessity of novel markers to predict treatment success and patient survival. This study aims to evaluate the prognostic and survival impact of flowytometry (FC) in CRC patients. : In this prospective study, 106 surgically resectable CRC patients were included. Tissue specimens from tumor and normal mucosa were collected and analyzed by FC. DNA and tumor index were calculated. In a subgroup of 46 patients, the CD26 expression on tumor cells was estimated. These parameters were compared with patients' tumor characteristics as stage, histology data, responsiveness to treatment, metastasis/recurrence, and, finally, patients' survival to identify possible new biomarkers. : The overall survival and the disease-specific survival in our study group was 76% and 72%, respectively, during the 7-year follow up period. Diploid tumors had better median survival than the aneuploid ones. The DNA index had significant correlation to the tumor index and response to neoadjuvant treatment. Similarly, the tumor index was also significantly related to the response to neoadjuvant treatment. Patients with a higher tumor index had worst survival rates. Surprisingly, CD26 levels were not associated with any of the parameters examined and were negatively related to tumor stage and differentiation. : FC is a rapid and reliable method of cell analysis. In CRC, it has been used for prognostic and diagnostic purposes. In this study, we have shown that DNA and tumor index could become predictive biomarkers of tumor response to neoadjuvant treatment and survival of resectable CRC patients.

References

Araujo S, Bernardo W, Habr-Gama A, Kiss D, Cecconello I . DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum. 2007; 50(11):1800-10. DOI: 10.1007/s10350-007-9013-6. View

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

Sinicrope F, Rego R, Halling K, Foster N, Sargent D, La Plant B . Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology. 2006; 131(3):729-37. DOI: 10.1053/j.gastro.2006.06.005. View

Weiser M . AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol. 2018; 25(6):1454-1455. DOI: 10.1245/s10434-018-6462-1. View

Georvasili V, Markopoulos G, Batistatou A, Mitsis M, Messinis T, Lianos G . Detection of cancer cells and tumor margins during colorectal cancer surgery by intraoperative flow cytometry. Int J Surg. 2022; 104:106717. DOI: 10.1016/j.ijsu.2022.106717. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Malki A, ElRuz R, Gupta I, Allouch A, Vranic S, Moustafa A . Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. Int J Mol Sci. 2020; 22(1). PMC: 7794761. DOI: 10.3390/ijms22010130. View

Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J . Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 2012; 27(9):1423-31. DOI: 10.1111/j.1440-1746.2012.07200.x. View

Laubert T, Freitag-Wolf S, Linnebacher M, Konig A, Vollmar B, Habermann J . Stage-specific frequency and prognostic significance of aneuploidy in patients with sporadic colorectal cancer--a meta-analysis and current overview. Int J Colorectal Dis. 2015; 30(8):1015-28. DOI: 10.1007/s00384-015-2259-x. View

10.

Hveem T, Merok M, Pretorius M, Novelli M, Baevre M, Sjo O . Prognostic impact of genomic instability in colorectal cancer. Br J Cancer. 2014; 110(8):2159-64. PMC: 3992498. DOI: 10.1038/bjc.2014.133. View

11.

Pang R, Lun Law W, Chu A, Poon J, Lam C, Chow A . A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell. 2010; 6(6):603-15. DOI: 10.1016/j.stem.2010.04.001. View

12.

Chen H, Feng L, Li M, Ju H, Ding Y, Lan M . College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer. Oncologist. 2021; 26(5):e780-e793. PMC: 8100558. DOI: 10.1002/onco.13707. View

13.

Laubert T, Bente V, Freitag-Wolf S, Voulgaris H, Oberlander M, Schillo K . Aneuploidy and elevated CEA indicate an increased risk for metachronous metastasis in colorectal cancer. Int J Colorectal Dis. 2013; 28(6):767-75. DOI: 10.1007/s00384-012-1625-1. View

14.

Darzynkiewicz Z, Huang X . Analysis of cellular DNA content by flow cytometry. Curr Protoc Immunol. 2008; Chapter 5:Unit 5.7. DOI: 10.1002/0471142735.im0507s60. View

15.

Mouradov D, Domingo E, Gibbs P, Jorissen R, Li S, Soo P . Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 2013; 108(11):1785-93. DOI: 10.1038/ajg.2013.292. View

16.

Marks K, West N, Morris E, Quirke P . Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. Br J Surg. 2018; 105(2):e99-e109. PMC: 7938848. DOI: 10.1002/bjs.10756. View

17.

Ng L, Foo D, Wong C, Man A, Lo O, Law W . Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study. Cancers (Basel). 2021; 13(14). PMC: 8306906. DOI: 10.3390/cancers13143588. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Galizia G, Gemei M, Orditura M, Romano C, Zamboli A, Castellano P . Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointest Surg. 2013; 17(10):1809-18. DOI: 10.1007/s11605-013-2258-6. View

20.

Koncina E, Haan S, Rauh S, Letellier E . Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers (Basel). 2020; 12(2). PMC: 7072488. DOI: 10.3390/cancers12020319. View